Skip to main content

Sublocade FDA Approval History

FDA Approved: Yes (First approved November 30, 2017)
Brand name: Sublocade
Generic name: buprenorphine
Dosage form: Sustained-Release Injection
Previous Name: RBP-6000
Company: Indivior PLC
Treatment for: Opiate Dependence

Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the treatment of opioid use disorder (OUD).

Development Timeline for Sublocade

Nov 30, 2017Approval  FDA Approves Sublocade (buprenorphine) Once-Monthly Injection for Opioid Use Disorder
Oct 31, 2017FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder
May 30, 2017Indivior Submits New Drug Application to U.S. FDA for RBP-6000 Buprenorphine Monthly Depot

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.